Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas

Journal: Nature Communications

Published: 2020-02-18

DOI: 10.1038/s41467-020-14642-0

Affiliations: 18

Authors: 35

Go to article
Institutions Share
German Consortium of Translational Cancer Research (DKTK), Germany 0.19
Department of Neuroradiology at Medical Faculty Heidelberg, Uni Heidelberg, Germany 0.17
Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, DKFZ, Germany 0.14
University Medical Centre Mannheim (UMM) at Medical Faculty Mannheim, Uni Heidelberg, Germany 0.12
Institute of Experimental Immunology, UZH, Switzerland 0.11
Division of Functional and Structural Genomics, DKFZ, Germany 0.06
Institute of Human Genetics at Medical Faculty Heidelberg, Uni Heidelberg, Germany 0.06
Clinical Cooperation Unit Neuropathology, DKFZ, Germany 0.04
Department of Neuropathology at Medical Faculty Heidelberg, Uni Heidelberg, Germany 0.04
Faculty of Biosciences, Uni Heidelberg, Germany 0.03
Department of Neurology at Medical Faculty Heidelberg, Uni Heidelberg, Germany 0.01
National Center for Tumor Diseases (NCT) Heidelberg, Germany 0.01
Clinical Cooperation Unit Neurooncology, DKFZ, Germany 0.01
Helmholtz Institute for Translational Oncology Mainz (HI-TRON Mainz), Germany 0.01
Institute of Neuroimmunology and Multiple Sclerosis, UHH, Germany 0.01
Immatics Biotechnologies GmbH, Germany 0.01

Return

Except where otherwise noted © 2020 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER